Why the study?
Does ramipril reduce arterial blood pressure and improve renal function in hypertensive single-kidney patients?
Does ramipril reduce arterial blood pressure and improve renal function in hypertensive single-kidney patients?
Ramipril effectively reduces blood pressure and microalbuminuria while improving renal hemodynamics in hypertensive patients with a single kidney.
Supports ramipril for BP control and renal protection in single-kidney hypertension; extends ACEI benefits to this high-risk population.
The effects of medium-term antihypertensive treatment with the ACE inhibitor ramipril were studied on 10 hypertensive single-kidney patients in a double-blind study versus placebo. Patients with renovascular hypertension were excluded. Compared to placebo, ramipril induces a significant reduction of arterial blood pressure (p < 0.02 for systolic, p < 0.01 for diastolic, and p < 0.05 for mean blood pressure), renal vascular resistance (p < 0.005), and microalbuminuria (p < 0.005), but a significant rise of effective renal plasma flow (p < 0.01) and no significant variation of the glomerular filtration rate. The reduction of microalbuminuria was not related to arterial blood pressure variation. Our study shows that ramipril, in appropriately selected-kidney patients, is effective and safe in reducing arterial blood pressure, bringing about an improvement of renal function and reducing microalbuminuria, which is frequently observed in this condition.
No takes yet. Share an insight, caveat, or question.
Camaiti et al. (1995) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: